Agile Therapeutics
AGILE THERAPEUTICS INC (Form: SC 13G/A, Received: 08/04/2017 13:23:26)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 2)*


Agile Therapeutics, Inc.
(Name of Issuer)


Common Stock, par value $0.0001 per share
(Title of Class of Securities)


00847L100
(CUSIP Number)


August 3, 2017
(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[_]  Rule 13d-1(b)

[X]  Rule 13d-1(c)

[_]  Rule 13d-1(d)

__________
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No
00847L100
   
     
1.
NAME OF REPORTING PERSONS
 
     
 
Caxton Corporation
 
     
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
   
(a)  [_]
   
(b)  [X]
     
3.
SEC USE ONLY
 
     
     
     
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
     
 
Delaware
 
     
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
5.
SOLE VOTING POWER
 
     
 
0
 
     
6.
SHARED VOTING POWER
 
     
 
1,654,317
 
     
7.
SOLE DISPOSITIVE POWER
 
     
 
0
 
     
8.
SHARED DISPOSITIVE POWER
 
     
 
1,654,317
 
     
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
 
1,654,317
 
     
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
   
[_]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
     
 
4.8%
 
     
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
CO
 


CUSIP No
00847L100
   
     
1.
NAME OF REPORTING PERSONS
 
     
 
CDK Associates, L.L.C.
 
     
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
   
(a)  [_]
   
(b)  [X]
     
3.
SEC USE ONLY
 
     
     
     
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
     
 
Delaware
 
     
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
5.
SOLE VOTING POWER
 
     
 
0
 
     
6.
SHARED VOTING POWER
 
     
 
1,483,752
 
     
7.
SOLE DISPOSITIVE POWER
 
     
 
0
 
     
8.
SHARED DISPOSITIVE POWER
 
     
 
1,483,752
 
     
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
 
1,483,752
 
     
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
   
[_]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
     
 
4.3%
 
     
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
OO
 



CUSIP No
00847L100
   
     
1.
NAME OF REPORTING PERSONS
 
     
 
Bruce S. Kovner
 
     
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
   
(a)  [_]
   
(b)  [X]
     
3.
SEC USE ONLY
 
     
     
     
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
 
     
 
United States
 
     
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
     
5.
SOLE VOTING POWER
 
     
 
0
 
     
6.
SHARED VOTING POWER
 
     
 
1,654,317
 
     
7.
SOLE DISPOSITIVE POWER
 
     
 
0
 
     
8.
SHARED DISPOSITIVE POWER
 
     
 
1,654,317
 
     
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
 
1,654,317
 
     
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
   
[_]
     
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
     
 
4.8%
 
     
12.
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
 


CUSIP No
00847L100
   

Item 1.
(a).
Name of Issuer:
 
       
   
Agile Therapeutics, Inc.
 

 
(b).
Address of Issuer's Principal Executive Offices:
 
       
   
101 Poor Farm Road
Princeton, New Jersey 08540
 

Item 2.
(a).
Name of Person Filing:
 
       
   
Caxton Corporation
CDK Associates, L.L.C.
Bruce S. Kovner
 

 
(b).
Address of Principal Business Office, or if None, Residence:
 
       
   
Caxton Corporation
731 Alexander Road,
Building 2, Suite 500
Princeton, New Jersey 08540
 
CDK Associates, L.L.C.
c/o Caxton Corporation
731 Alexander Road,
Building 2, Suite 500
Princeton, New Jersey 08540
 
Bruce S. Kovner
c/o Caxton Corporation
731 Alexander Road,
Building 2, Suite 500
Princeton, New Jersey 08540
 

 
(c).
Citizenship:
 
       
   
Caxton Corporation – Delaware corporation
CDK Associates, L.L.C. – Delaware limited liability company
Bruce S. Kovner – United States citizen
 

 
(d).
Title of Class of Securities:
 
       
   
Common Stock, par value $0.0001 per share
 

 
(e).
CUSIP Number:
 
       
   
00847L100
 
 
Item 3.
 
If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

 
(a)
[_]
Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
 
 
(b)
[_]
Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).

 
(c)
[_]
Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).

 
(d)
[_]
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 
(e)
[_]
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

 
(f)
[_]
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

 
(g)
[_]
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 
(h)
[_]
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);

 
(i)
[_]
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 
(j)
[_]
Group, in accordance with s.240.13d-1(b)(1)(ii)(J).



Item 4.
Ownership.

 
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 
(a)
Amount beneficially owned:
     
   
1,654,317 shares deemed beneficially owned by Caxton Corporation
1,483,752 shares deemed beneficially owned by CDK Associates, L.L.C.
1,654,317 shares deemed beneficially owned by Bruce S. Kovner

 
(b)
Percent of class:
     
   
4.8% deemed beneficially owned by Caxton Corporation
4.3% deemed beneficially owned by CDK Associates, L.L.C.
4.8% deemed beneficially owned by Bruce S. Kovner

 
(c)
Number of shares as to which Caxton Corporation has:
 
 
(i)
Sole power to vote or to direct the vote
0
,
       
 
(ii)
Shared power to vote or to direct the vote
1,654,317
,
       
 
(iii)
Sole power to dispose or to direct the disposition of
0
,
       
 
(iv)
Shared power to dispose or to direct the disposition of
1,654,317
.

 
Number of shares as to which CDK Associates, L.L.C. has:

 
(i)
Sole power to vote or to direct the vote
0
,
       
 
(ii)
Shared power to vote or to direct the vote
1,483,752
,
       
 
(iii)
Sole power to dispose or to direct the disposition of
0
,
       
 
(iv)
Shared power to dispose or to direct the disposition of
1,483,752
.

 
Number of shares as to which Bruce S. Kovner has:

 
(i)
Sole power to vote or to direct the vote
0
,
       
 
(ii)
Shared power to vote or to direct the vote
1,654,317
,
       
 
(iii)
Sole power to dispose or to direct the disposition of
0
,
       
 
(iv)
Shared power to dispose or to direct the disposition of
1,654,317
.

Item 5.
Ownership of Five Percent or Less of a Class.

 
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
 
 
Item 6.
Ownership of More Than Five Percent on Behalf of Another Person.

 
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
 
 
1,483,752 shares of the Issuer are held in the account of CDK Associates, L.L.C., an entity of which Caxton Corporation is the Manager.  Bruce S. Kovner is the Chairman and sole shareholder of Caxton Corporation.  170,565 shares of the Issuer are held in the accounts of employees of an affiliate of Caxton Corporation.
   

Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
 
 
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
 
 
N/A
   


Item 8.
Identification and Classification of Members of the Group.

 
If a group has filed this schedule pursuant to § 240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
 
N/A
   

Item 9.
Notice of Dissolution of Group.

 
Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
 
 
N/A
   

Item 10.
Certification.

 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect , other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 
CAXTON CORPORATION*
     
   
 
By:
/s/ Heath N. Weisberg
 
Name:
Heath N. Weisberg
 
Title:
General Counsel and Chief Compliance Officer
     
     
 
CDK ASSOCIATES, L.L.C.
     
 
By:  Caxton Corporation, its manager
   
 
By:
/s/ Heath N. Weisberg
 
Name:
Heath N. Weisberg
 
Title:
General Counsel and Chief Compliance Officer
     
     
 
BRUCE S. KOVNER*
     
   
 
By:
/s/ Heath N. Weisberg
 
Name:
Heath N. Weisberg
 
Title:
Attorney-in-Fact for Bruce S. Kovner**
     
 
 August 4, 2017


* The Reporting Persons disclaim beneficial ownership in the Shares reported herein except to the extent of their pecuniary interest therein.
** Power of attorney is incorporated herein by reference to Exhibit B to the Schedule 13G filed by Caxton Corporation on April 29, 2016.
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Note.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.
Attention.  Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit A
AGREEMENT
The undersigned agree that this Amendment No. 2 to Schedule 13G dated August 4, 2017 relating to the Common Stock, par value $0.0001 per share of Agile Therapeutics, Inc., shall be filed on behalf of the undersigned.
 
CAXTON CORPORATION*
     
   
 
By:
/s/ Heath N. Weisberg
 
Name:
Heath N. Weisberg
 
Title:
General Counsel and Chief Compliance Officer
     
     
 
CDK ASSOCIATES, L.L.C.
     
 
By:  Caxton Corporation, its manager
   
   
 
By:
/s/ Heath N. Weisberg
 
Name:
Heath N. Weisberg
 
Title:
General Counsel and Chief Compliance Officer
     
     
 
BRUCE S. KOVNER*
     
   
 
By:
/s/ Heath N. Weisberg
 
Name:
Heath N. Weisberg
 
Title:
Attorney-in-Fact for Bruce S. Kovner**
     
 
August 4, 2017